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Nowadays obesity and its related diseases represent a major health problem with 
an increasing worldwide prevalence. Hyperplasia and hypertrophy of adipocytes lead 
to an excessive fat accumulation that is not effi  ciently prevented by current pharmaco-
logical treatments. So the research on anti-obesity drugs with good effi  cacy and toler-
ability able both to prevent and to reduce fat accumulation is of pivotal interest.
In the present study we evaluated in vitro the eff ects of Valproic Acid, Berber-
in and Resveratrol on adipogenesis. Our experimental model was represented by 
human Mesenchymal Stem Cells (hMSCs), physiological precursors of adipocytes 
that can diff erentiate into adipocytes also in vitro.
Preliminary cytotoxicity assays were performed in order to choose non-toxic dos-
es of the three drugs. hMSCs were induced to adipogenic diff erentiation and treated 
with Valproic Acid, Berberin and Resveratrol at the selected doses. Controls were rep-
resented by hMSCs treated for adipogenesis in absence of the drugs.
At diff erent time points intracellular lipid droplets accumulation, a typical fea-
ture of adipogenesis, was assessed by Oil Red O staining. Valproic Acid, Berberin and 
Resveratrol inhibited hMSCs adipogenic diff erentiation in a dose dependent manner 
as demonstrated by the reduction of the lipid droplets accumulation.
To understand the molecular mechanisms of the drugs-induced adipogenesis inhi-
bition, we focused our attention on the eff ects of the drugs treatment on cell cycle 
progression, known to be altered by many antiadipogenic drugs, and on the MAP 
Kinases ERK1 and ERK2, involved in the adipogenesis control. We evaluated the 
expression of cyclins and CDKs by immunoblotting and ﬂ ow-cytometry analyses, 
demonstrating that Valproic Acid, Berberin and Resveratrol interfere on cell cycle 
progression. The expression and the phosphorylation status of the two kinases ERK1 
and ERK2 were assessed by immunoblotting demonstrating an increase of ERK1 
phosphorylation (i.e. activation) in hMSCs treated with Berberin and a reduction 
in hMSCs treated with Valproic Acid and Resveratrol compared to control cells. No 
changes in phosphorylation and expression of ERK2 were observed.
Our study demonstrate that Valproic Acid, Berberin and Resveratrol exert an 
anti-adipogenic eff ect in our experimental model. The mechanisms of action of these 
drugs involve the alteration of cell cycle progression and, at least in part, ERK1/2 
modulation. However other molecular pathways are likely implicated and other 
studies are required to identify them.
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